Compare Oracle Corporation (ORCL) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance

Oracle CorporationTrade

State Street SPDR S&P Biotech ETFTrade

Price performance (Past 24H)

Key statistics

Oracle Corporation vs State Street SPDR S&P Biotech ETF — how do they compare? Oracle Corporation trades at $162.65 (market cap $468.13B), while State Street SPDR S&P Biotech ETF trades at $160. The key difference: Oracle Corporation pays a 1.23% dividend while State Street SPDR S&P Biotech ETF pays none, and State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, Oracle Corporation nearer its low. Which is the better fit depends on your goals.

	ORCL	XBI
Market Cap	$468.13B	—
Sector	Technology	Broad Market / Factor
52-Week High	$328.33	$169.55
52-Week Low	$114.99	$93.43
Enterprise Value	$597.38B	—
Dividend Yield	1.23%	—

View details →View details →

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Oracle Corporation

Oracle (ORCL) trades at $161.70, up 1.81% today, with a bullish technical signal and strong earnings beats in recent quarters. Revenue grew to $57.40B in 2025, with net income margin expanding to 25.37%. The stock is supported by positive AI infrastructure developments and a consensus analyst price target of $243.38, indicating significant upside potential from current levels.

The outlook remains positive driven by AI partnerships and cloud growth, but risks include high valuation multiples and rising capital expenditures. Institutional sentiment is bullish with 65% buy ratings, though legal scrutiny and competitive pressures warrant monitoring for sustained momentum.

State Street SPDR S&P Biotech ETF

XBI trades at $161.97, down 1.12% today, with technical indicators showing mixed signals amid a bearish overall trend. The ETF holds over 150 biotech companies and has rallied 76% in the past year, driven by M&A activity and positive clinical trial catalysts. Analyst coverage remains limited with a single hold rating, while recent news highlights sector optimism around cancer vaccine breakthroughs and improved capital access.

Outlook remains cautiously optimistic with potential for 8-14% returns over 6-12 months, though high volatility and regulatory risks persist. Key opportunities include ongoing pharmaceutical M&A and innovation in immunotherapy, while risks center on sector-specific volatility and policy uncertainty.

Aura AI is an analytical signal, not financial advice — do your own research.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

ORCL

Oracle's cloud contracts surge 363%, stock down 31%, investor bullish on AI infrastructure growth.24/7 Wall Street · 17 hours agoBullish OpenAI plans $750B compute spend by 2030 but faces capacity and funding challenges impacting Oracle.24/7 Wall Street · 17 hours agoNeutral Fed meeting looms over Amazon and Oracle's costly AI cloud expansions amid negative cash flow.24/7 Wall Street · 18 hours agoNeutral View details →

XBI

Biotech ETF IBB outperformed S&P 500 by 22 points in 3 months amid pharma patent cliff deals.24/7 Wall Street · 2 days agoBullish State Street SPDR S&P Biotech ETF (XBI) rated Buy with 8%-14% returns expected despite prior 76% rallySeeking Alpha · 4 days agoBullish View details →

About Oracle Corporation

Oracle provides database technology and enterprise resource planning, or ERP, software to enterprises around the world. Founded in 1977, Oracle pioneered the first commercial SQL-based relational database management system. Today, Oracle has 430,000 customers in 175 countries, supported by its base of 136,000 employees.

About State Street SPDR S&P Biotech ETF

XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.